KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $6.1 million.

  • Xenon Pharmaceuticals' Change in Accured Expenses rose 439.60% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 100.99%. This contributed to the annual value of $8.5 million for FY2024, which is 117.02% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Change in Accured Expenses of $6.1 million as of Q3 2025, which was up 598.73% from $869,000 recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Change in Accured Expenses registered a high of $9.2 million during Q2 2024, and its lowest value of -$5.8 million during Q1 2022.
  • Its 3-year average for Change in Accured Expenses is $1.4 million, with a median of $869,000 in 2025.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 875.05% in 2021, then plummeted by 744.78% in 2024.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Change in Accured Expenses stood at $3.8 million in 2021, then spiked by 60.14% to $6.0 million in 2022, then tumbled by 61.76% to $2.3 million in 2023, then spiked by 168.75% to $6.2 million in 2024, then skyrocketed by 439.60% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $869,000 for Q2 2025, and -$3.8 million during Q1 2025.